Maze Therapeutics’ Claims For Unapproved Kidney Disease Drug Face Regulatory Scrutiny

 
• By Sue Sutter
  
Winner
Vertex objected to claims that Maze's kidney disease drug offered better potency and efficacy. (Shutterstock)

More from Marketing & Advertising

More from United States